TYROBP

Across TCGA pan-cancer cohorts, TYROBP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TYROBP data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TYROBP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TYROBP expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TYROBP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.239	0.572	.003	50	view →
CCRCC	DFS	Median	III,IV	0.543	0.806	.015	8	view →
LUAD	OS	Median	All	0.922	0.999	.014	7	view →
GBM	OS	Quartile	All	0.431	0.720	.011	6	view →
LSCC	OS	Quartile	III,IV	0.970	0.553	.033	6	view →
UCEC	OS	Median	III,IV	1.000	0.560	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TYROBP–PDAC (DFS)

Open the PDAC breakdown →